What makes a pathogen antibiotic-resistant?

Understanding the underlying mechanisms of acquired antimicrobial resistance is critical to the fight, a case of knowing one's enemy. In a new paper published March 2, 2024 in npj Antimicrobials and Resistance, part of the Nature Portfolio, researchers at Sanford Burnham Prebys, working with Roche Pharma Research and Early Development, describe how two notable pathogens -- Escherichia coli and Acinetobacter baumannii -- employ distinctly different tools to fend off antibiotic attack.

"This work was conceived as a comparative study of the mechanisms and dynamics of resistance acquisition for two drugs and two bugs," said senior author Andrei L. Osterman, Ph.D., at Sanford Burnham Prebys.

"Comparing mutational landscapes triggered by the same drug in two distinct bugs allows us to deduce both shared and unique evolutionary trajectories toward resistance. A comparison of two drugs in the same bug reveals shared and unique mechanistic features of fundamental and translational importance, from drug discovery to rational optimization of treatment regimens."

Both pathogens studied are gram-negative bacteria with shared characteristics, but also notable differences.

For the most part, E. coli is a bacterium routinely found in the guts of humans and animals, where it resides with no ill effect. Some strains, however, do cause harm, everything from mild gastroenterological distress to urinary tract infections, respiratory illness and pneumonia.

Acinetobacter baumannii is more problematic, particularly in clinical settings where it can cause severe infections, some life-threatening.

Both bacteria have developed resistance to most current antibiotic treatments.

In their paper, Osterman and colleagues combined experimental evolution in a continuous culturing device (morbidostat) with whole genome sequencing of evolving cultures to track how E. coli and A. baumannii acquired drug resistance against a pair of antibiotics that inhibit DNA gyrase, an essential enzyme in bacteria.

Inhibiting the enzyme disrupts DNA synthesis and, subsequently, causes the bacteria to die. One antibiotic -- ciprofloxacin -- has been in active clinical use since 1987; the other -- GP6 -- is experimental.

The researchers found that pathogenic bacteria with acquired resistance to ciprofloxacin remained susceptible to effective antimicrobial treatment by GP6 drug. However, the opposite was not true: evolution of resistance to GP6 also triggered resistance to ciprofloxacin.

These findings underscored that E. coli and A. baumannii employ shared and unique mechanisms to acquire resistance to these two types of drugs.

"Bacteria acquire resistance as a result of random mutational events that happen in the DNA replication as uncorrected 'typos'," said Osterman. "These spontaneously emerge in a handful of drug-resistant variants/strains out of godzillions of neutral mutations) under selective pressure."

(A godzillion is a descriptive term, not a precise unit of measurement. It refers to a number of enormous size. In this case a number ranging between 10⁸ to 10⁹ neutral mutations.)

These harmful mutations may underlie several types of resistance mechanisms, including modifying the protein targets of a given drug, the ability of bacterial cells to expel compounds (drugs) before they cause harm (efflux) and special bacterial enzymes that inactivate active drug compounds.

Osterman said the work advances progress toward developing "resistibility profiles" of established and novel antimicrobial drugs, which would help set forth "boundaries for possible combinational treatment, including clinically relevant multidrug resistant strains. Our acquired knowledge provides crucial guidelines for all these translational activities."

The findings are not limited to E. coli and A. baumannii. They have potential to at least partially predict resistance drivers across other closely related species posing significant health risks, including Pseudomonas, Salmonella and Klebsiella spp. all difficult-to-treat bacterial pathogens linked to serious and sometimes deadly infections.

Additional authors on the study include Semen A. Leyn, James E. Kent, Jaime E. Zlamal and Marinela L. Elane, all at Sanford Burnham Prebys; and Maarten Vercruysse, Rocha Pharma.

The study was supported by F. Hoffmann-La Roche Ltd and the National Institute of Allergy and Infectious Diseases (grant 5R01AI167977).

The study's DOI is 10.1038/s44259-024-00021-y